Ophthalmic drug products, such as eye drops, pose a heightened risk of harm to users because drugs applied to the eyes bypass some of the body’s natural defenses. Any drug used in the eyes must be sterile to reduce the risk of infection. Eye drops are available by prescription or sold as OTCs.
Similar Posts
CDER SBIA On-Demand Learning Library
FDA’s CDER Small Business and Industry Assistance (SBIA) is making available our YouTube learning library – now hundreds of our recordings are readily accessible.In Response to a Broader FDA Investigation, ByHeart Initiates a Voluntary Recall of Two Batches of Infant Formula
[New York, NY] – ByHeart, a next-generation baby nutrition company, announced today that, out of an abundance of caution, it has chosen to voluntarily recall two batches of ByHeart Whole Nutrition Infant Formula following notification from the U.S. Food and Drug Administration (FDA) of a broader ongAbdallah Candies Issues a Voluntary Recall of Pecan Caramel Clusters Due to Undeclared, Mislabeled Allergens
Abdallah Candies is voluntarily recalling a specific lot of Pecan Caramel Clusters, due to a mislabeled allergen. Product contains Cashews that were not listed on the product label. Product was sold and distributed exclusively to Lunds & Byerlys, as a private label, sold in the state of Minnesota.GDUFA Paid Facilities List
This list contains GDUFA facility payments received by the Agency. Data are extract from the User Fee System and GDUFA Facility User Fee Coversheets. The following table explains the terms used in the list:www.soma4ever.com – 706082 – 06/13/2025
Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the InternetEndo Expands Voluntary Recall of Clonazepam Orally Disintegrating Tablets, USP (C-IV) Due to Potential Product Carton Strength Mislabeling
Endo, Inc. (OTCQX: NDOI) (“Endo”) announced today that one of its operating subsidiaries, Endo USA, Inc., is expanding its previously announced voluntary recall of Clonazepam Orally Disintegrating Tablets, USP (C-IV) due to potential product carton strength mislabeling.